Bryan, Garnier & Co announces that the total proceeds of Galapagos IPO on Nasdaq, the largest Nasdaq IPO of a European biotech, have been raised to $317m following the full exercise of over-allotment option.
Share the transaction
London, May 19th, 2015 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces that the Nasdaq IPO of Galapagos NV, a major European clinical-stage biotechnology company, raised $317m including the full exercise of the greenshoe option. Bryan, Garnier & Co is the only European investment bank in the IPO syndicate. The IPO of Galapagos on Nasdaq confirms the strong momentum of the European healthcare sector.
The global offering of Galapagos NV (Euronext: GLPG), initially filed for $150 million, reached gross proceeds of $317 million including the full exercise of the greenshoe option. The new shares were placed in a concurrent public offering in the US through ADSs for $42.05 and private placement in Europe for €37 per share. The greenshoe option representing 15% of the global offering, was exercised in full. It is the largest Nasdaq IPO of European biotech and one of three largest biotech IPO ever in Europe or the US.
Bryan, Garnier & Co acted as Co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura.
Bryan Garnier & Co keeps on leading the financing of the European healthcare companies, in Europe and the US:
- Bryan, Garnier & Co was the only European investment bank involved in the top 5 IPOs of European healthcare companies on Nasdaq, i.e. Galapagos (Belgium), DBV Technology (France), Forward Pharma (Denmark), Cellectis (France) and Adaptimune (UK), as well as in the IPO of LDR Holding (US/France).
- Bryan, Garnier & Co confirms its leading position in the financing of the European emerging biopharma industry, through private equity placements, PIPEs, and public offerings, on both the European and the American equity capital markets (LSE, AIM, Euronext, Alternext, and Nasdaq OMX).
- Cumulated placements managed by Bryan, Garnier & Co in healthcare exceeded 1b€ over the past 24 months including 3 Nasdaq IPOs (Galapagos, DBV Technologies and LDR Holding).
For more information, please contact Anna Emelianenko (aemelianenko@bryangarnier.com | + 33 1 56 68 75 00)